In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio
Read about Royalty Pharma's $94 million acquisition of a royalty interest in IBD therapy Entyvio from Massachusetts General Hospital’s (MGH).
Source: ibdnewstoday.com